Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Mohammed, Asia ^a   Ndaro, Arnold ^a   Kalinga, Akili ^b   Manjurano, Alphaxard ^b   Mosha, Jackline F ^b   Mosha, Dominick F ^a   Van Zwetselaar, Marco ^a   Koenderink, Jan B ^c   Mosha, Frank W ^a   Alifrangis, Michael ^d   Reyburn, Hugh ^a,e   Roper, Cally ^e   Kavishe, Reginald A ^a  

^a KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chloroquine; Drug resistance; Malaria; Mutations; Parasites; Pfcrt; Plasmodium falciparum; Polymorphisms; Tanzania

Indexed keywords

AMODIAQUINE; ARTEMISININ; CHLOROQUINE; K76T PROTEIN; PFCRT PROTEIN; PROTOZOAL DNA; PROTOZOAL PROTEIN; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CODON; DNA EXTRACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENOTYPE; HUMAN; MALARIA; MICROBIAL POPULATION DYNAMICS; MOZAMBIQUE; NONHUMAN; PLASMODIUM FALCIPARUM; PREGNANCY; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANZANIA; TEST STRIP; TREND STUDY; WILD TYPE;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DNA, PROTOZOAN; DRUG RESISTANCE; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREGNANCY; PROTOZOAN PROTEINS; TANZANIA; YOUNG ADULT;

EID: 84887334412     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-415     Document Type: Article

References (43)

1. Spread of chloroquine resistance in Plasmodium falciparum. Payne D, Parasitol Today 1987 3 241 246 10.1016/0169-4758(87)90147-5 15462966 (Pubitemid 17142151)
2. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863 (Pubitemid 36724485)
3. Chloroquine resistance before and after its withdrawal in Kenya. Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A, Malar J 2009 8 106 10.1186/1475-2875-8-106 19450282
4. Tanzania phases out chloroquine for the treatment of malaria. Taverne J, Trends Parasitol 2001 17 360
5. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, Mills A, Trop Med Int Health 2006 11 452 461 10.1111/j.1365-3156.2006.01590.x 16553928
6. In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Gorissen E, Ashruf G, Lamboo M, Bennebroek J, Gikunda S, Mbaruku G, Kager PA, Trop Med Int Health 2000 5 459 463 10.1046/j.1365-3156.2000.00570.x 10929148 (Pubitemid 30469983)
7. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH, Trans R Soc Trop Med Hyg 2002 96 674 676 10.1016/S0035-9203(02)90349-4 12630380 (Pubitemid 36231495)
8. The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania. Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, McHomvu N, Abdulla S, Bloland P, Mills A, Malar J 2008 7 4 10.1186/1475-2875-7-4 18179716 (Pubitemid 351313746)
9. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE, Proc Natl Acad Sci USA 2009 106 9027 9032 10.1073/pnas.0901415106 19451638
10. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE, Clin Infect Dis 2011 53 224 230 10.1093/cid/cir376 21765070
11. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. Harrington WE, Morrison R, Fried M, Duffy PE, PLoS One 2013 8 56183 10.1371/journal.pone.0056183 23451036
12. Intermittent preventive treatment for malaria in sub-Saharan Africa: a halfway technology or a critical intervention? Vinetz JM, Am J Trop Med Hyg 2010 82 755 756 10.4269/ajtmh.2010.825editorial 20439949
13. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Chico RM, Pittrof R, Greenwood B, Chandramohan D, Malar J 2008 7 255 10.1186/1475-2875-7-255 19087267
14. The ABCs of multidrug resistance in malaria. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG, Trends Parasitol 2010 26 440 446 10.1016/j.pt.2010.05.002 20541973
15. Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. Warhurst DC, Malar J 2003 2 31 10.1186/1475-2875-2-31 14599295
16. Chloroquine-resistant malaria. Wellems TE, Plowe CV, J Infect Dis 2001 184 770 776 10.1086/322858 11517439 (Pubitemid 32826429)
17. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC, Am J Trop Med Hyg 2009 80 523 527 19346369
18. Temporal trends of molecular markers associated with artemether- lumefantrine tolerance/resistance in Bagamoyo district. Tanzania. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Bjorkman A, Martensson A, Malar J 2013 12 103 10.1186/1475-2875-12-103 23506218
19. Rapid and effective processing of blood specimens for diagnostic PCR using filter paper and Chelex-100. Polski JM, Kimzey S, Percival RW, Grosso LE, Mol Pathol 1998 51 215 217 10.1136/mp.51.4.215 9893748 (Pubitemid 28394271)
20. A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by chloroquine treatment in Tanzania. Schneider AG, Premji Z, Felger I, Smith T, Abdulla S, Beck HP, Mshinda H, Infect Genet Evol 2002 1 183 189 10.1016/S1567-1348(01)00021-1 12798014 (Pubitemid 34461231)
21. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Schonfeld M, Barreto MI, Schunk M, Maduhu I, Maboko L, Hoelscher M, Berens-Riha N, Kitua A, Loscher T, Malar J 2007 6 2 10.1186/1475-2875-6-2 17224049 (Pubitemid 46169629)
22. The roles of the pfcrt 76 T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Khalil IF, Alifrangis M, Tarimo DS, Staalso T, Satti GM, Theander TG, Ronn AM, Bygbjerg IC, Ann Trop Med Parasitol 2005 99 441 448 10.1179/136485905X46441 16004703 (Pubitemid 40992388)
23. Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania. Temu EA, Kimani I, Tuno N, Kawada H, Minjas JN, Takagi M, Am J Trop Med Hyg 2006 75 1182 1187 17172390 (Pubitemid 351627505)
24. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A, Fidock DA, Gil JP, J Infect Dis 2009 199 750 757 10.1086/596738 19210165
25. High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. Lemnge M, Alifrangis M, Kafuye MY, Segeja MD, Gesase S, Minja D, Massaga JJ, Ronn AM, Bygbjerg IC, Am J Trop Med Hyg 2006 75 188 193 16896117 (Pubitemid 46941329)
26. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, Enevold A, Ronn AM, Khalil IF, Warhurst DC, Lemnge MM, Theander TG, Bygbjerg IC, J Infect Dis 2006 193 1738 1741 10.1086/504269 16703518 (Pubitemid 43839479)
27. Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine? Kamugisha E, Bujila I, Lahdo M, Pello-Esso S, Minde M, Kongola G, Naiwumbwe H, Kiwuwa S, Kaddumukasa M, Kironde F, Swedberg G, Acta Trop 2012 121 148 151 10.1016/j.actatropica.2011.11.004 22118982
28. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G, Malar J 2012 11 58 10.1186/1475-2875-11-58 22369089
29. Adoption of the new antimalarial drug policy in Tanzania-a cross-sectional study in the community. Eriksen J, Nsimba SE, Minzi OM, Sanga AJ, Petzold M, Gustafsson LL, Warsame MY, Tomson G, Trop Med Int Health 2005 10 1038 1046 10.1111/j.1365-3156.2005.01486.x 16185239 (Pubitemid 41445069)
30. Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. Thomsen TT, Madsen LB, Hansson HH, Tomas EV, Charlwood D, Bygbjerg IC, Alifrangis M, Am J Trop Med Hyg 2013 88 536 541 10.4269/ajtmh.12-0525 23382159
31. Detection of copy number variation and single nucleotide polymorphisms in genes involved in drug resistance and other phenotypic traits in P. falciparum clinical isolates collected from Uganda. Kiwuwa MS, Byarugaba J, Wahlgren M, Kironde F, Acta Trop 2013 125 269 275 10.1016/j.actatropica.2012.11.013 23220229
32. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ, Antimicrob Agents Chemother 2010 54 1200 1206 10.1128/AAC.01412-09 20065051
33. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Enosse S, Magnussen P, Abacassamo F, Gomez-Olive X, Ronn AM, Thompson R, Alifrangis M, Malar J 2008 7 115 10.1186/1475-2875-7-115 18590577 (Pubitemid 352033072)
34. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI, PLoS One 2011 6 25992 10.1371/journal.pone.0025992 22022487
35. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch AE, Venkatesan M, Laufer MK, Malar J 2011 10 116 10.1186/1475-2875-10-116 21554692
36. Prescribing practices for malaria in a rural Ugandan hospital: evaluation of a new malaria treatment policy. Ucakacon PS, Achan J, Kutyabami P, Odoi AR, Kalyango NJ, Afr Health Sci 2011 11 1 53 59
37. Community referral in home management of malaria in western Uganda: a case series study. Kallander K, Tomson G, Nsungwa-Sabiiti J, Senyonjo Y, Pariyo G, Peterson S, BMC Int Health Hum Rights 2006 6 2 10.1186/1472-698X-6-2 16539744
38. Malaria treatment policy change and implementation: the case of Uganda. Nanyunja M, Nabyonga OJ, Kato F, Kaggwa M, Katureebe C, Saweka J, Malar Res Treat 2011 2011 683167 22312571
39. Health service providers in Somalia: their readiness to provide malaria case-management. Noor AM, Rage IA, Moonen B, Snow RW, Malar J 2009 8 100 10.1186/1475-2875-8-100 19439097
40. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M, Am J Trop Med Hyg 2011 85 979 983 10.4269/ajtmh.2011.11-0071 22144430
41. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of March 2013 meeting. WHO-MPAC, Malar J 2013 12 213 23787092
42. Fansidar-resistant Plasmodium falciparum infection from Tanzania. Vleugels MP, Wetsteyn JC, Meuwissen JH, Trop Geogr Med 1982 34 263 265 6758246 (Pubitemid 13213428)
43. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Minja DT, Schmiegelow C, Mmbando B, Bostrom S, Oesterholt M, Magistrado P, Pehrson C, John D, Salanti A, Luty AJ, Lemnge M, Theander T, Lusingu J, Alifrangis M, Emerg Infect Dis 2013 doi: 10.3201/eid1909.130133